Lb Pharmaceuticals (LBRX) Interest Expenses (2025 - 2026)
Lb Pharmaceuticals' (LBRX) quarterly Interest Expenses came in at $24.4 million in Q1 2026, up 73900.0% year-on-year from N/an in Q1 2025, and up 13317.58% quarter-over-quarter from $182000.0 in Q4 2025.
Lb Pharmaceuticals (LBRX) Interest Expenses (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Interest Expenses history runs 2 years deep, the most recent figure standing at $24.4 million for Q1 2026.
- On a quarterly basis, Interest Expenses rose 73900.0% year-over-year to $24.4 million in Q1 2026; TTM through Mar 2026 was $24.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $29.7 million, up 26.85% from the prior year.
- Interest Expenses grew to $24.4 million in Q1 2026 per LBRX's latest filing, from $182000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $24.4 million in Q1 2026 and bottomed at $33000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Lb Pharmaceuticals | 977.73 Mn | 977.73 Mn | - | 24.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.42 Mn |
| Mar 31, 2026 | 24.42 Mn |
| Dec 31, 2025 | 182,000.00 |
| Dec 31, 2025 | 182,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |